Scholarlink

Background <p>Drug interactions with diagnostic radiopharmaceuticals are well recognized, as they can modify biodistribution and lead to false or misleading diagnostic results. However, little is known about such interactions in the field of therapeutic radiopharmaceuticals, despite their rapid expansion—particularly with targeted radionuclide therapies such as Radioligand Therapy (RLT). This review aims, for the first time, to systematically compile and analyze available data on drug interactions involving therapeutic radiopharmaceuticals, in order to support safer and more effective patient care.</p> Main body <p>Eighty-three articles investigating drug interactions with [<sup>177</sup>Lu]Lu-oxodotreotide (Lutathera®), [<sup>177</sup>Lu]Lu-vipivotide tetraxetan (Pluvicto®), [<sup>131</sup>I]INa, [<sup>131</sup>I]I-meta-iodobenzylguanidine ([<sup>131</sup>I]I-MIBG), [<sup>223</sup>Ra]RaCl<sub>2</sub> (Xofigo®), [<sup>90</sup>Y]Y-ibritumomab tiuxetan (Zevalin®) or [<sup>153</sup>Sm]Sm-lexidronam pentasodium (Quadramet®) were included. These studies reported 133 drug interactions, 69% of which were not mentioned in the corresponding summaries of product characteristics. Interactions could be beneficial (e.g., reducing renal toxicity) or harmful (e.g., decreasing therapeutic efficacy or potentiating toxicity). Three interactions involved complementary and alternative medicines (quercetin, Ginkgo biloba and ouabain).</p> <p>Overall, the evidence level for reported interactions was low: 88% were classified as level 3 or 4 according to the Centre for Evidence-Based Medicine (CEBM) scale.</p> Conclusion <p>Drug interactions with therapeutic radiopharmaceuticals remain underreported, yet they may have significant clinical consequences. Clinical radiopharmacy plays a key role in detecting and preventing these interactions. Radiopharmacists, through their expertise, can identify potential interactions, influence therapeutic decisions, and positively impact patient management. Their involvement throughout the care pathway is essential to ensure the safe and effective use of these innovative therapies. Nuclear medicine physicians should also be aware that such interactions can alter biodistribution, compromise therapeutic efficacy, and increase the risk of adverse effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Drug interactions involving therapeutic radiopharmaceuticals: a systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月26日

查看全文
  • Robin Gacon,
  • Romane Chapuis,
  • Luca Fabris-Davet,
  • Nina Ranjit,
  • Sylvain Goutelle,
  • Laurent Bourguignon,
  • Anthime Flaus,
  • Claire Bolot,
  • Elise Levigoureux,
  • Matthieu Gallet,
  • Sarah Chaib

摘要

Background

Drug interactions with diagnostic radiopharmaceuticals are well recognized, as they can modify biodistribution and lead to false or misleading diagnostic results. However, little is known about such interactions in the field of therapeutic radiopharmaceuticals, despite their rapid expansion—particularly with targeted radionuclide therapies such as Radioligand Therapy (RLT). This review aims, for the first time, to systematically compile and analyze available data on drug interactions involving therapeutic radiopharmaceuticals, in order to support safer and more effective patient care.

Main body

Eighty-three articles investigating drug interactions with [177Lu]Lu-oxodotreotide (Lutathera®), [177Lu]Lu-vipivotide tetraxetan (Pluvicto®), [131I]INa, [131I]I-meta-iodobenzylguanidine ([131I]I-MIBG), [223Ra]RaCl2 (Xofigo®), [90Y]Y-ibritumomab tiuxetan (Zevalin®) or [153Sm]Sm-lexidronam pentasodium (Quadramet®) were included. These studies reported 133 drug interactions, 69% of which were not mentioned in the corresponding summaries of product characteristics. Interactions could be beneficial (e.g., reducing renal toxicity) or harmful (e.g., decreasing therapeutic efficacy or potentiating toxicity). Three interactions involved complementary and alternative medicines (quercetin, Ginkgo biloba and ouabain).

Overall, the evidence level for reported interactions was low: 88% were classified as level 3 or 4 according to the Centre for Evidence-Based Medicine (CEBM) scale.

Conclusion

Drug interactions with therapeutic radiopharmaceuticals remain underreported, yet they may have significant clinical consequences. Clinical radiopharmacy plays a key role in detecting and preventing these interactions. Radiopharmacists, through their expertise, can identify potential interactions, influence therapeutic decisions, and positively impact patient management. Their involvement throughout the care pathway is essential to ensure the safe and effective use of these innovative therapies. Nuclear medicine physicians should also be aware that such interactions can alter biodistribution, compromise therapeutic efficacy, and increase the risk of adverse effects.